Connections between TET proteins and aberrant DNA modification in cancer

Trends in Genetics

Volumn 30, Issue 10, 2014, Pages 464-474

  Huang, Yun ^a,b,c   Rao, Anjana ^a,b  

^a La Jolla Spine Institute   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

5 hydroxymethylcytosine; 5hmC; 5mC; Cancer; DNA demethylation; DNA methylation; IDH; OGT; TET

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5 CARBOXYLCYTOSINE; 5 FORMYLCYTOSINE; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; AGI 5198; AGI 6780; ANTIOXIDANT; ASCORBIC ACID; AZACITIDINE; CYSTEINE; CYTOSINE DERIVATIVE; DIOXYGENASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; ENZYME INHIBITOR; FERROUS ION; GENOMIC DNA; GLUTATHIONE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE INHIBITOR; MICRORNA 22; N ACETYLGLUCOSAMINE; O LINKED BETA N ACETYLGLUCOSAMINE TRANSFERASE; TEN ELEVEN TRANSLOCATION PROTEIN; TRANSFERASE; UNCLASSIFIED DRUG; 5-CARBOXYLCYTOSINE; 5-FORMYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DECITABINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; MOLECULAR LIBRARY; ONCOPROTEIN; TET1 PROTEIN, HUMAN; TET3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CARCINOGENESIS; CELL METABOLISM; CHEMICAL STRUCTURE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; DRUG TARGETING; EMBRYONIC STEM CELL; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIVER TUMOR; LOSS OF FUNCTION MUTATION; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MOLECULE; MOUSE MODEL; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA SPLICING; SOLID TUMOR; STEREOISOMERISM; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; MOLECULAR LIBRARY; MUTATION; NEOPLASM;

5-METHYLCYTOSINE; AZACITIDINE; CYTOSINE; DIOXYGENASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA-BINDING PROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; ISOCITRATE DEHYDROGENASE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84921989642     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2014.07.005     Document Type: Review

References (144)

1. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
2. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
3. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
4. Ooi S.K., et al. Mammalian cytosine methylation at a glance. J. Cell Sci. 2009, 122:2787-2791.
5. Bostick M., et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007, 317:1760-1764.
6. Sharif J., et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007, 450:908-912.
7. Tahiliani M., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
8. He Y.F., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
9. Ito S., et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
10. Pastor W.A., et al. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 2013, 14:341-356.
11. Wu H., Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 2014, 156:45-68.
12. Hashimoto H., et al. Selective excision of 5-carboxylcytosine by a thymine DNA glycosylase mutant. J. Mol. Biol. 2013, 425:971-976.
13. Zhang L., et al. Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat. Chem. Biol. 2012, 8:328-330.
14. Maiti A., Drohat A.C. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J. Biol. Chem. 2011, 286:35334-35338.
15. Kohli R.M., Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013, 502:472-479.
16. Ono R., et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002, 62:4075-4080.
17. Meyer C., et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23:1490-1499.
18. Delhommeau F., et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360:2289-2301.
19. Langemeijer S.M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842.
20. Abdel-Wahab O., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
21. Itzykson R., et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J. Clin. Oncol. 2013, 31:2428-2436.
22. Tefferi A., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
23. Grossmann V., et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011, 25:877-879.
24. Figueroa M.E., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
25. Nibourel O., et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116:1132-1135.
26. Weissmann S., et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012, 26:934-942.
27. Konstandin N., et al. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 2011, 25:1649-1652.
28. Bejar R., et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364:2496-2506.
29. Bejar R., et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 2011, 29:504-515.
30. Liu W.J., et al. Prognostic significance of TET2 mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leuk. Lymphoma 2014, 10.3109/10428194.2014.893308.
31. Euba B., et al. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia. Leuk. Lymphoma 2012, 53:1230-1233.
32. Ko M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
33. Hu L., et al. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell 2013, 155:1545-1555.
34. Lin T.L., et al. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica 2014, 99:28-36.
35. Kosmider O., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.
36. Kosmider O., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676-1681.
37. Smith A.E., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116:3923-3932.
38. Pronier E., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555.
39. Liu X., et al. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk. Lymphoma 2013, 54:2466-2473.
40. Haferlach T., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28:241-247.
41. Papaemmanuil E., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616v3627. quiz 3699.
42. Odejide O., et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014, 123:1293-1296.
43. Lemonnier F., et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012, 120:1466-1469.
44. Itzykson R., et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013, 121:2186-2198.
45. Quivoron C., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
46. Moran-Crusio K., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
47. Ko M., et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14566-14571.
48. Li Z., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
49. Busque L., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 2012, 44:1179-1181.
50. Hanssens K., et al. SRSF2-P95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 2014, 99:830-835.
51. Meggendorfer M., et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012, 120:3080-3088.
52. Yoshida K., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
53. Graubert T.A., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 2012, 44:53-57.
54. Papaemmanuil E., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 2011, 365:1384-1395.
55. Zhang S.J., et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012, 119:4480-4485.
56. Gelsi-Boyer V., et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br. J. Haematol. 2010, 151:365-375.
57. Muto T., et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 2013, 210:2627-2639.
58. Abdel-Wahab O., et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 2013, 210:2641-2659.
59. Simon J.A., Kingston R.E. Occupying chromatin: polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol. Cell 2013, 49:808-824.
60. Scheuermann J.C., et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010, 465:243-247.
61. Sakata-Yanagimoto M., et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 2014, 46:171-175.
62. Palomero T., et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 2014, 46:166-170.
63. Couronne L., et al. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 2012, 366:95-96.
64. Seshagiri S., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
65. Sato Y., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013, 45:860-867.
66. Nickerson M.L., et al. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum. Mutat. 2013, 34:1231-1241.
67. Yang H., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2012, 32:663-669.
68. Jin S.G., et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71:7360-7365.
69. Song S.J., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
70. Lian C.G., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
71. Hsu C.H., et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012, 2:568-579.
72. Sun M., et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9920-9925.
73. Kim Y.H., et al. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J. Clin. Pathol. 2011, 64:850-852.
74. Cheng J., et al. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep. 2013, 5:471-481.
75. Hu X., et al. Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell 2014, 14:512-522.
76. Liu C., et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS ONE 2013, 8:e62828.
77. Ko M., et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 2013, 497:122-126.
78. Hino S., et al. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol. Cell. Biol. 2001, 21:330-342.
79. Iyer L.M., et al. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 2009, 8:1698-1710.
80. Paez D., et al. Association of common gene variants in the WNT/beta-catenin pathway with colon cancer recurrence. Pharmacogenomics J. 2014, 14:142-150.
81. Kojima T., et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 2009, 28:297-305.
82. Wang Y., Zhang Y. Regulation of TET protein stability by calpains. Cell Rep. 2014, 6:278-284.
83. Storr S.J., et al. The calpain system and cancer. Nat. Rev. Cancer 2011, 11:364-374.
84. Warburg O., et al. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 7:519-530.
85. Love D.C., Hanover J.A. The hexosamine signaling pathway: deciphering the "O-GlcNAc code". Sci. STKE 2005, 2005:re13.
86. Vosseller K., et al. Diverse regulation of protein function by O-GlcNAc: a nuclear and cytoplasmic carbohydrate post-translational modification. Curr. Opin. Chem. Biol. 2002, 6:851-857.
87. Ozcan S., et al. Modulation of transcription factor function by O-GlcNAc modification. Biochim. Biophys. Acta 2010, 1799:353-364.
88. Sakabe K., et al. Beta-N-acetylglucosamine (O-GlcNAc) is part of the histone code. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19915-19920.
89. Fujiki R., et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 2011, 480:557-560.
90. Fong J.J., et al. beta-N-Acetylglucosamine (O-GlcNAc) is a novel regulator of mitosis-specific phosphorylations on histone H3. J. Biol. Chem. 2012, 287:12195-12203.
91. Myers S.A., et al. Polycomb repressive complex 2 is necessary for the normal site-specific O-GlcNAc distribution in mouse embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9490-9495.
92. Chu C.S., et al. O-GlcNAcylation regulates EZH2 protein stability and function. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1355-1360.
93. Chen Q., et al. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 2013, 493:561-564.
94. Deplus R., et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J. 2013, 32:645-655.
95. Vella P., et al. Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol. Cell 2013, 49:645-656.
96. Ito R., et al. TET3-OGT interaction increases the stability and the presence of OGT in chromatin. Genes Cells 2014, 19:52-65.
97. Shi F.T., et al. Ten-eleven translocation 1 (Tet1) is regulated by O-linked N-acetylglucosamine transferase (Ogt) for target gene repression in mouse embryonic stem cells. J. Biol. Chem. 2013, 288:20776-20784.
98. Zhang Q., et al. Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked beta-N-acetylglucosamine transferase (OGT). J. Biol. Chem. 2014, 289:5986-5996.
99. Slawson C., et al. A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin. Mol. Biol. Cell 2008, 19:4130-4140.
100. Goto H., et al. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 2002, 7:11-17.
101. Yang W.H., et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat. Cell Biol. 2006, 8:1074-1083.
102. Itkonen H.M., et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 2013, 73:5277-5287.
103. Olivier-Van Stichelen S., et al. The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of beta-catenin and cell proliferation. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E417-E424.
104. Loenarz C., Schofield C.J. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem. Sci. 2011, 36:7-18.
105. Dang L., et al. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 2010, 16:387-397.
106. Losman J.A., et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
107. Ye D., et al. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 2013, 23:274-276.
108. Koivunen P., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
109. Lu C., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
110. Sasaki M., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488:656-659.
111. Kats L.M., et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014, 14:329-341.
112. Xiao M., et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012, 26:1326-1338.
113. Adam J., et al. Rare insights into cancer biology. Oncogene 2014, 33:2547-2556.
114. Englard S., Seifter S. The biochemical functions of ascorbic acid. Annu. Rev. Nutr. 1986, 6:365-406.
115. Yang X., et al. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 2010, 31:536-546.
116. Santi D.V., et al. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 1983, 33:9-10.
117. Yan X., et al. 5-Azacytidine improves the osteogenic differentiation potential of aged human adipose-derived mesenchymal stem cells by DNA demethylation. PLoS ONE 2014, 9:e90846.
118. Wang F., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013, 340:622-626.
119. Rohle D., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
120. Kaelin W.G. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:335-345.
121. Banhegyi G., et al. Subcellular compartmentation of ascorbate and its variation in disease states. Biochim. Biophys. Acta 2014, 1843:1909-1916.
122. Yin R., et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 2013, 135:10396-10403.
123. Minor E.A., et al. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J. Biol. Chem. 2013, 288:13669-13674.
124. Blaschke K., et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013, 500:222-226.
125. Dickson K.M., et al. Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate. Biochem. Biophys. Res. Commun. 2013, 439:522-527.
126. Ficz G., et al. FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell 2013, 13:351-359.
127. Nytko K.J., et al. Vitamin C is dispensable for oxygen sensing in vivo. Blood 2011, 117:5485-5493.
128. Pfaffeneder T., et al. Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. Nat. Chem. Biol. 2014, 10:574-581.
129. Cortellino S., et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146:67-79.
130. Lister R., et al. Global epigenomic reconfiguration during mammalian brain development. Science 2013, 341:1237905.
131. Dawlaty M.M., et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9:166-175.
132. Dawlaty M.M., et al. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev. Cell 2013, 24:310-323.
133. Koh K.P., et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8:200-213.
134. Ito S., et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
135. Huang Y., et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1361-1366.
136. Lorsbach R.B., et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
137. Huang H., et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:11994-11999.
138. Kalender Atak Z., et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS ONE 2012, 7:e38463.
139. Kunimoto H., et al. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci. Rep. 2012, 2:273.
140. Madzo J., et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 2014, 6:231-244.
141. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
142. Berman B.P., et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 2012, 44:40-46.
143. Yamazaki J., et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012, 7:201-207.
144. Patel J.P., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 2012, 366:1079-1089.